Clinical Trials Logo

Clinical Trial Summary

PICC related venous thrombosis (PICC-RVT) is one of the common complications of PICC and the main cause of unplanned extubation. Effectively identifying the risk of PICC-RVT in patients and preventing PICC-RVT are of great clinical significance. There are many studies on the risk factors of VTE at home and abroad, and there are also many studies on the risk assessment of PICC catheter-related thrombosis, mostly focusing on sociodemographic data, comorbidities, and intubation related factors, while the research on laboratory related indicators is limited It involves D-dimer, white blood cell count (WBC), platelet count (PLT), etc., but its specificity or positive predictive value is not high, and there is no reliable biomarker report. Studies have shown that the decrease or lack of AT-Ⅲ, PC, PS activity is one of the mechanisms of hypercoagulable state in patients with cancer, and may be a biomarker of thrombosis. Many retrospective studies have also shown that the activities of AT-Ⅲ, PC, and PS are related to the occurrence and recurrence of VTE and DVT. The pathogenesis is mainly anticoagulant protein defect or decreased expression. However, when PICC is implanted in patients with AT-Ⅲ, PC and PS activity defects, whether PICC indwelling will become a predisposing factor of thrombosis is not yet known. Therefore, the purpose of this study is to understand the rate of anticoagulant protein deficiency in patients with tumor PICC-RVT, and to prospectively explore the correlation between the lack of AT-Ⅲ, PC, and PS activities and PICC-RVT, and to provide targeted preventive interventions for PICC-RVT patients Scientific basis.


Clinical Trial Description

A prospective study showed that a mild reduction in AT levels (70%-80%) was associated with the recurrence of no incentive VTE. Subsequent studies defined mild AT deficiency as less than the 5th percentile of the normal range to further verify that mild AT deficiency is a risk factor for VTE recurrence. Many retrospective studies have also shown that the activities of AT-Ⅲ, PC and PS are related to the occurrence and recurrence of VTE and DVT. Taking the lower limit of the normal reference value as the criterion for judging the lack of anticoagulant protein activity, Zhu Tienan et al. found that the lack of activity of AT, PC, and PS in normal people were 1.15%, 1.49%, and 2.29%, respectively. Fang Biqian et al. found 277 cases of VTE. Among the cases found that the lack of activity of AT, PC, and PS were 16.00%, 17.45%, and 17.09%, respectively. That is, the lack of activity of the three anticoagulant proteins in VTE patients was about 10 times higher than that of normal people. Chinese scholars from Taiwan, Hong Kong and Shanghai also found that the total lack of three anticoagulant proteins of AT-Ⅲ, PC and PS exceeds 15% in Western countries, suggesting that the etiological composition of venous thromboembolism in the Chinese population may be similar to that of Western countries. Different, reflecting that anticoagulant protein deficiency plays an important role in the pathogenesis of VTE patients in China. Compared with factor V Leiden mutation and prothrombin 20210A mutation, the most common thrombosis in Asian population is antithrombin Ⅲ (AT-Ⅲ), protein C (protein C, PC) and protein S (protein S, PS), etc. Defects of anticoagulant protein. When the hypercoagulable state caused by anticoagulant protein deficiency is induced by certain risk factors for thrombosis, such as pregnancy, oral contraceptives, fractures, long-term immobilization, etc., it can lead to the occurrence of VTE. When PICC is implanted in patients with AT-Ⅲ, PC and PS activity defects, whether PICC indwelling will become a predisposing factor of thrombosis is not yet known.

It has been reported that the severity of CVC-related thrombosis in patients with AT-Ⅲ deficiency after CVC catheterization is higher than that of the normal group. Nowak-Göttl et al. showed that PC and PS genetic defects are related to catheterization in children Thrombosis plays an important role. In 2016, a systematic review showed that the risk of DVT related to more than one anticoagulant defect increased by 3.20 times. PC defects can increase the incidence of CVC-related DVT in children. Our preliminary study of this subject found that the lack of anticoagulant protein in PICC-RVT patients was higher than that in non-PICC-RVT patients. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04535206
Study type Observational
Source Second Affiliated Hospital, School of Medicine, Zhejiang University
Contact Yun Shi, Bachelor
Phone 0571-87783887
Email t574404873@163.com
Status Recruiting
Phase
Start date August 30, 2018
Completion date October 30, 2021

See also
  Status Clinical Trial Phase
Not yet recruiting NCT06417541 - Autopsy and Photon Counting Computed Tomography to Evaluate Thromboses Related to Central Venous Catheters
Completed NCT04503135 - Catheter Associated Asymptomatic Thrombosis in Intensive Care Unit
Completed NCT03766828 - Dialysis Catheter Placement in Patients With Thoracic Central Venous Occlusion
Completed NCT01708850 - Study in Cancer Patients With Central Line Associated Clots in the Upper Extremity Treated With Rivaroxaban (Catheter 2) Phase 4
Recruiting NCT03100071 - Central Venous Catheter (CVC) Associated Deep Vein Thrombosis (DVT) in Cancer Patients
Recruiting NCT04548713 - CLiCK in the Critical Care Unit N/A
Completed NCT03506815 - Thromboprophylaxis With Rivaroxaban In Patients With Malignancy and Central Venous Lines Phase 3
Completed NCT04767113 - Continuous Heparin Infusion to Prevent Catheter-related Thrombosis N/A
Not yet recruiting NCT04774588 - HoloStream Study - Video Capture Device Usage N/A
Recruiting NCT05033314 - THromboprophylaxis In Sickle Cell Disease With Central Venous Catheters (THIS) Phase 3
Completed NCT01779999 - Early Detection of PICC-related Deep Vein Thrombosis by US Surveillance: an Effective Approach for Secondary Prevention? N/A
Recruiting NCT03157245 - Incidence of Deep Vein Thrombosis on Central Venous Catheters in the Post Operative Period of Carcinologic Surgery N/A
Enrolling by invitation NCT05188339 - The Effectiveness and Safety of 4% Sodium Citrate as a Lock Solution in Central Venous Hemodialysis Catheter Phase 2/Phase 3
Not yet recruiting NCT05455866 - Central Venous Catheter-related Complications in Patients Under Anticancer Treatment
Not yet recruiting NCT02264964 - Duration and Adverse Events of Non-cuffed Catheter in Patients With Hemodialysis N/A
Enrolling by invitation NCT03841240 - The Central Venous Catheter Related Complications in Critically Ill Patients
Completed NCT04302376 - Thrombotic Complications After Central Venous Catheterization
Completed NCT03327376 - Daily Ultrasound-screening for CVC-related Thrombosis
Completed NCT03672006 - t-PA Prophylaxis to Prevent Catheter-associated Thrombosis and Infection Phase 2